November 13-15, 2018

Boston, MA, USA

Twitter logo for website footers 2

Speakers Faculty


Mark Ma
Senior Director, Bioanalytical and Biomarker Development
Alexion Research

Mark Ma is Senior Director of Bioanalytical and Biomarker Development at Alexion Research. Prior to Alexion Mark was the director of large molecule Bioanalytical Sciences at Amgen. His group provides bioanalytical and biomarker support to preclinical and clinical drug development, including large molecule, gene therapy, and small molecules. Mark had held several academic research positions with UCLA and MMRI prior to joining Amgen. Mark is an active member of AAPS and service as lead of PK assay working group.

Mingjun Huang
Senior Vice President & Head of Research
Achillion Pharmaceuticals

Dr. Huang joined Achillion in 2001 and currently serves as Senior Vice President and Head of Research. Dr. Huang began her tenure at Achillion as Director of Biology and has advanced through her outstanding contributions to the Company’s discovery efforts and innovations in building the portfolio. She is a pioneer in the discovery and development of the first oral factor D inhibitor, ACH-4471, as well as the next-generation compounds. Dr. Huang received her medical training at Shanghai Medical School, Fudan University, her Ph.D. at the University of New Mexico, and her postdoctoral training at the National Institutes of Health. She was a research fellow at National Cancer Institute and also head of antiviral research at Southern Research Institute prior to joining Achillion.  

Anna Borodovsky
Associate Director
Alnylam Inc

Dr. Borodovsky has been developing siRNA-based therapeutics at Alnylam for over 11 years. More recently she has focused on the complement system and has lead the preclinical development of cemdisiran a C5-targeted siRNA currently in Phase 2 clinical testing. Dr. Borodovsky is a biochemist/immunologist by training and has held positions at the Broad Institute and Biogen prior to joining Alnylam.

Lukas Scheibler
Executive Vice President, Research and Translatable Medicine
Apellis Pharmaceuticals

Dr. Scheibler joined Apellis in April 2018 as Executive Vice President for Research and Translational Medicine. In this role, he will be responsible to create and manage all preclinical research projects and advance them into clinical development to establish proof of concept. Dr. Scheibler is an R&D professional with in depth experiences in drug development. He most recently was head of R&D at Acucela, a Seattle based startup and had a 13-year career in research and development, business development and clinical development at Novartis. He holds a PhD from the University of Lausanne, Switzerland and a post doctoral training at Harvard Medical School.

Rajinder Singh
Senior Vice President of Research

Dr. Singh has served as our Senior Vice President, Research since May 2016. Prior to joining us, Dr. Singh held various management positions at Rigel Pharmaceuticals, Inc. (Rigel). Most recently and for the past ten years, Dr. Singh was Vice President, Chemistry at Rigel, where he oversaw the advancement of several drug candidates from discovery to clinical development, which included the filing of numerous Investigational New Drug applications in the areas of immunology and oncology. Prior to joining Rigel, Dr. Singh was a lead chemist at Chiron Corporation from 1994 to 1998. From 1992 to 1994, Dr. Singh was a Postdoctoral Fellow at Eli Lilly & Company. Dr. Singh received his Ph.D. degree in Organic Chemistry from the University of Oxford.

Mel Berger
Senior Medical Director, Immunology R&D
CSL Behring

Mel Berger earned undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University. He trained in pediatrics at Boston Children’s and allergy-immunology at NIH, and is Board Certified in both. He was Assistant Chief of Allergy-Immunology at Walter Reed and Assistant Professor at the Uniformed Services University. In 1984, he returned to Cleveland as Chief of Allergy-Immunology at Rainbow, Babies and Children’s Hospital, and rose to Professor of Pediatrics, Pathology and General Medical Sciences (Oncology) at Case Western Reserve.  In 2008, he became a Senior Medical Director at CSL-Behring, and he continues holding a faculty appointment at Case.

Frank Baas
Chief Scientific Officer
Complement Pharma

Professor Frank Baas,  CSO of Complement Pharma and head of the Laboratory of Diagnostic Genome Analysis at  Leiden University Medical Center, obtained his MD (1982) and his PhD (1986) at the University of Amsterdam. Did a post-doctoral training at Harvard University, Massachusetts Institute of Technology and the Netherlands Cancer Institute. In 2002 he was appointed professor of Neurogenetics at the AMC, University of Amsterdam, where he identified a role of the terminal pathway in nerve regeneration and founded Regenesance. His current research is focussed on the role of complement in neurological disease. He developed antibodies and anti-sense molecules MAC inhibitors, which is are now under development at Complement Pharma.  

Sharookh Kapadia
Sr. Scientist and Project Team Leader, Infectious Diseases

Sharookh Kapadia is a Sr. Scientist and Project Team leader in the Department of Infectious Diseases and Genentech.  Dr. Kapadia oversees multiple antibacterial and antiviral drug discovery projects using both biologic and small molecule approaches with the goal of directly targeting the pathogen while, at the same time, enhancing immune-mediated bacterial clearance.  Prior to Genentech, Sharookh was a Scientist at Gilead Sciences in Foster City, CA. Sharookh completed his postdoctoral training with Dr. Francis V. Chisari at The Scripps Research Institute where he uncovered a novel requirement for lipid metabolism in HCV replication. He received his Ph.D. in Immunology from Washington University in St. Louis, MO.

Adam Rogers
Chief Executive Officer
Hemera Biosciences

Adam Rogers, MD is the CEO and a Founder of Hemera Biosciences, an innovative biotechnology company focused on preserving vision in a manner that is convenient to the patient and reduces the treatment burden.  Hemera is currently focused on blocking the final step of the complement cascade, membrane attack complex (MAC), via an intravitreal injection that is performed in an office setting. Prior to Hemera, Dr. Rogers served as a retina specialist at the New England Eye Center in Boston, MA for 16 years.

Niels Riedemann
Chief Executive Officer

Professor Riedemann is founder of InflaRx and has served as Chief Executive Officer since 2007. He is trained and board certified general surgeon and intensive care physician. He served as Vice Director of Intensive Care Medicine at the Friedrich Schiller University in Jena, Germany from 2008 to 2015. He spent several years working in basic science at the University of Michigan in the field of complement immunology and inflammation and was heading several funded complement research grants as principle investigator.. His research has been awarded several national and international awards and he has published over 50 highly ranked scientific articles.

Michael McCaleb
Vice President, Clinical Development
Ionis Pharmaceuticals

During his career in pharmaceutical and biotech companies, Dr. McCaleb has led the discovery of over a dozen drugs that have advanced into development.  In addition, he has also played a major role in the clinical development of numerous drugs, several of them achieving international commercialization.  Most of his research has been devoted to the discovery of novel therapeutics for metabolic, neurological, ophthalmology and rare diseases.  Currently, Dr. McCaleb is Vice President of Clinical Development at Ionis Pharmaceuticals.

Mike Ero
Chief Executive Officer
Machaon Diagnostics

Mr. Ero is the president and CEO of Machaon Diagnostics, a company he founded in 2003. He brings an entrepreneurial approach to laboratory medicine, designing new and innovative laboratory services to meet unmet needs in the healthcare and bioscience industries. With over 20 years of experience in medical laboratory diagnostics, Mr. Ero and his team of scientists have pioneered multiple disruptive laboratory techniques and processes that have revolutionized how life-threatening diseases can be managed and characterized. He has been primary investigator on over 130 clinical trials and studies with physical, molecular, immunologic, platelet and special coagulation endpoints.

Andrew Luster
Chief, Division of Rheumatology, Allergy and Immunology & Director, Center for Immunology and Inflammatory Diseases
Massachusetts General Hospital

Dr. Luster received his B.S. from Duke University, his Ph.D. from Rockefeller University under the mentorship of Drs. Jeffrey Ravetch and Zanvil Cohn, and his M.D. from Cornell University Medical College.  Dr. Luster pursued a residency in medicine and a fellowship in infectious diseases at Massachusetts General Hospital, followed by a post-doctoral research fellowship in Dr. Philip Leder’s laboratory in the Department of Genetics at Harvard Medical School. Dr. Luster is Chief of the Division of Rheumatology, Allergy and Immunology, the Director of the Research Center for Immunology and Inflammatory Diseases, and the E. Alexandria and Michael N. Altman Chair in Immunology at Massachusetts General Hospital.  He is also the Persis, Cyrus and Marlow B. Harrison Professor of Medicine at Harvard Medical School.  

Dimitrios Kapogiannis
Clinical Investigator
National Institute of Neurological Disorders and Stroke

Dimitrios Kapogiannis graduated from the University of Athens Medical School. He completed his training in Neurology at Massachusetts General Hospital/Harvard Medical School and Behavioral Neurology at NINDS/NIH. He is Clinical Investigator at the Laboratory of Neurosciences at NIA/NIH conducting translational studies in Alzheimer's disease and adjunct Associate Professor at the Department of Neurology at Johns Hopkins University. His research focus is on Extracellular Vesicles as a source of biomarkers and as effectors in neurodegenerative disease pathogenesis. He also conducts clinical trials in Alzheimer’s disease targeting brain metabolism.  

Workshop B

Tuesday 13th November

13.00pm | Circulating Extracellular Vesicles of Neuronal and Astrocytic Origin: Carriers of Complement Biomarkers and Effectors in Alzheimer’s Disease Pathogenesis

Simon Read
Chief Scientific Officer
Ra Pharma

Simon has been Chief Scientific Officer at Ra Pharma since April 2016. Prior to joining the company, he served as Vice President and Head of the Innovative Medicines Unit (IMU) at Grünenthal GmbH, a pharmaceutical company headquartered in Aachen, Germany from 2014 to 2016. Prior to that, Simon served as Vice President and Head of Global Biomedical Sciences at Grünenthal GmbH from 2011 to 2014. Before joining Grünenthal, he was the Director, Experimental Medicine and Biomarkers, Immunology with Roche Products/Genentech Inc. from 2008 to 2011. Simon has been a member of the Medical Research Council and Association of British Pharmaceutical Industry Steering Committee for the UK’s foremost Immunology Consortium since 2012. He has been a member of the Boston Children’s Hospital Technology Development Fund steering group since 2016. Simon received his B.Sc. in Physiology from University of Manchester, a M.Sc. from University of Southampton and a Ph.D. from University of Hertfordshire.

Barbara Klughammer
Senior Principal Scientist
Roche Pharma Research and Early Development

Barbara joined Roche 2002 where she has filed therapeutics and diagnostic assays in various indications. Currently she conducts early clinical trials in complement driven diseases

Dan Granoff
Clarox Endowed Chair and Director, Center for Immunobiology and Vaccine Development
UCSF Benioff Children’s Hospital Oakland Research Institute

Dan M. Granoff, M.D., holds the Clorox Endowed Chair and is Director of the Center for Immunobiology and Vaccine Development at UCSF Benioff Children’s Hospital, Oakland, California. Author of more than 220 articles in infectious diseases, microbiology and vaccine research, his work over the last decade has focused on meningococcal Factor H binding protein, which is now part of two licensed vaccines, and the effect of complement inhibitors on immunity to meningococcal disease. In 2014 he was the recipient of the Maurice Hilleman/Merck Laureate award by the American Society of Microbiology for outstanding contributions to vaccine discovery and development.

Workshop A

Tuesday 13th November

09.00am | Explore the Safety Risks of Meningococcal Disease as a Result of Complement Inhibition

Sanjay Ram
Professor of Medicine
University of Massachusetts Medical School

Sanjay Ram is currently a Professor in the Division of Infectious Diseases and Immunology at the University of Massachusetts Medical School. His group has a long-standing interest in studying how the pathogenic Neisseriae (Neisseria gonorrhoeae and N. meningitidis) interact with the complement system and escape killing by complement. This knowledge is now being used to design novel immunotherapeutics and vaccines against multidrug-resistant gonorrhea that has spread globally.

Workshop A

Tuesday 13th November

09.00am | Explore the Safety Risks of Meningococcal Disease as a Result of Complement Inhibition

Robert Peters
Senior Vice President Research
Bioverativ, a Sanofi company

Dr. Peters leads the Research group at Bioverativ, a Sanofi Company, working to discover, design and develop new therapeutic options to address the unmet medical needs in hemophilia, hemoglobinopathies, and complement-mediated blood disorders such as cold agglutinin disease.  Dr. Peters has worked on extended half-life clotting factor fusion proteins, including Eloctate (rFVIIIFc), Alprolix (rFIXFc), and BIVV001 (rFVIIIFc-VWF-XTEN), since their inception.  More recently, Bioverativ acquired True North Therapeutics and has advanced BIVV009 (anti-C1s antibody) into phase 3 studies in cold agglutinin disease. Dr. Peters has a B.S. degree from Cornell University and PhD in Biochemistry and Molecular Biology from Harvard University.

Day One

Wednesday 14th November

09.00 | Chair’s Opening Remarks

Day Two

Thursday 15th November

09.00 | Chairman’s Opening Remarks

Thomas Schall
Chief Executive Officer

Dr. Schall is the founder of our company and has served as our President, Chief Executive Officer and Director since we commenced operations in 1997 and was appointed Chairman of the Board in April 2012. From 1993 to 1997, Dr. Schall worked at the DNAX Research Institute, a division of Schering-Plough Corporation. Prior to his work at the DNAX Research Institute, he worked as a scientist with Genentech, Inc. Dr. Schall participated in some of the earliest discoveries of chemokine system function and activities. Dr. Schall cloned one of the first chemokines to be discovered, and provided some of the earliest data for the existence of the previously unknown family of molecules which later came to be called the chemokines. Dr. Schall’s laboratories have been responsible for the discovery or co-discovery of a large percentage of all known chemokine receptors. Dr. Schall received his B.S. in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University.

Martin Schmidt
Chief Scientific Officer
Kypha, Inc.

Since joining Kypha in 2015, Martin has led multiple clinical research collaborations and an NIH-funded technology development program (SBIR) that resulted in successful assay development and clinical proof-of-concept for pathway-specific monitoring of complement activation dynamics at the bedside using Kypha’s Comp act® platform. Prior to Kypha, he spent 10 years in academic biomedical research and technology development. Martin received his PhD in neuroscience from Vanderbilt University and completed postdoctoral training at Washington University in St. Louis as a W.M. Keck Fellow in Molecular Medicine.